The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) asked CRA to evaluate the policies that host governments of middle-income countries use to encourage investment in innovative activities and the implications for future innovation. CRA consultants looked at eight countries and concluded that there are six key lessons that appear to be critical for success. Read more in the article here:
What is driving obesity market growth and what does that mean for manufacturers?
Are GLP-1 weight-loss therapies growing primarily by expanding the treatment population or by capturing share from existing obesity therapies? Obesity afflicts...